The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | CheckMate 9LA study: nivo + ipi in NSCLC
Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, highlights data coming from the CheckMate 9LA study which evaluated nivolumab in combination with ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles of chemotherapy as first-line treatment for stage IV/reccurent non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),
